Glaukos (GKOS) Earns Media Impact Rating of 0.21

Headlines about Glaukos (NYSE:GKOS) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Glaukos earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 46.0786272203236 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern’s analysis:

Shares of Glaukos (GKOS) opened at $25.65 on Tuesday. Glaukos has a 12 month low of $23.08 and a 12 month high of $52.49. The firm has a market cap of $900.43 and a PE ratio of -855.00.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.06. Glaukos had a negative net margin of 0.64% and a positive return on equity of 3.50%. The business had revenue of $40.41 million during the quarter, compared to analysts’ expectations of $38.69 million. During the same quarter in the previous year, the company earned $0.03 EPS. The business’s revenue was up 36.6% on a year-over-year basis.

Several analysts recently commented on GKOS shares. Stifel Nicolaus reaffirmed a “buy” rating on shares of Glaukos in a report on Thursday, September 14th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $38.00 target price on shares of Glaukos in a report on Friday, September 15th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $60.00 target price on shares of Glaukos in a report on Tuesday, November 7th. BMO Capital Markets reaffirmed a “buy” rating and set a $45.00 target price on shares of Glaukos in a report on Wednesday, October 18th. Finally, Zacks Investment Research downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a report on Wednesday, September 20th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Glaukos has a consensus rating of “Buy” and an average price target of $44.86.

In other Glaukos news, CFO Joseph E. Gilliam acquired 2,100 shares of the company’s stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $23.84 per share, for a total transaction of $50,064.00. Following the purchase, the chief financial officer now directly owns 102,100 shares of the company’s stock, valued at $2,434,064. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 16.40% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: “Glaukos (GKOS) Earns Media Impact Rating of 0.21” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Insider Buying and Selling by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply